Loading the records…
Loading the records…
HR2623 mandates the VA to establish five innovative therapies centers focused on advanced treatments including psychedelics. The bill is in early committee stage with 27 cosponsors and no appropriated funding yet. The tickers CMPS, GHRS, ATAI, and DRUG have rallied significantly over 30 days (17% to 52%) on the Executive Order and legislative signal, but remain well below 52-week highs.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
The four pure-play psychedelic developers (CMPS $8.39, GHRS $19.27, ATAI $4.17, DRUG $88.97) have already priced in significant legislative optimism with 30-day gains of 17-52%. The 7-day pullback (CMPS -12.4%, ATAI -9.9%) suggests the market is repricing the probability and timeline of actual appropriations. These stocks remain highly speculative — they are all below their 52-week highs (CMPS: 82% of high, GHRS: 78%, ATAI: 62%, DRUG: 72%) and face binary risk from the appropriations process. Investors should monitor the House VA Committee markup schedule and any FY2027 VA appropriations language. The structural bull case is intact — the VA is the ideal early adopter — but near-term momentum has stalled as the legislative reality (zero funding, early stage) sets in.
HR2623, the 'Innovative Therapies Centers of Excellence Act of 2025,' was introduced in the House on April 3, 2025, by Rep. Correa (D-CA) and referred to the House Veterans' Affairs Committee. The bill requires the VA to designate at least five medical facilities as innovative therapies centers to research and deliver advanced treatments, explicitly including psychedelic-based therapies for conditions like PTSD and depression. A companion bill (S4031) has been introduced in the Senate, and an Executive Order has separately directed acceleration of psychedelic treatment reviews.
Crucially, the bill authorizes the establishment of these centers but explicitly states operations are 'subject to the availability of appropriations.' This is an authorization bill — it sets policy direction and creates a legal framework, but allocates zero dollars. Actual funding requires a separate appropriations bill. The bill has 27 cosponsors (bipartisan: Correa, Bergman, Crenshaw, Khanna, Luttrell) but remains in early committee stage with only four actions to date.
The psychedelic therapy sector has four publicly traded pure-plays: CMPS ($8.39), GHRS ($19.27), ATAI ($4.17), and DRUG ($88.97). All four have rallied sharply over the past 30 days (CMPS +51.7%, GHRS +37%, ATAI +17.8%, DRUG +21.9%) following the Executive Order announcement. However, the 7-day trend is negative (CMPS -12.4%, GHRS -4.9%, ATAI -9.9%, DRUG -0.2%), suggesting the initial Executive Order pop is fading as investors recognize the authorization-appropriation gap.
The structural winners remain the pure-play psychedelic developers because the VA represents the single largest concentrated patient population for PTSD/depression (over 1 million veterans diagnosed). Unlike the commercial insurance path (requiring lengthy reimbursement approvals), a VA center of excellence can directly procure and administer therapies. However, the legislative timeline is lengthy: the bill must pass committee, pass the House, pass the Senate (companion S4031 helps), and then secure an appropriations rider. This is a multi-year catalyst, not an imminent revenue event.
Matched on shared policy language across AI analyses, with ticker & timing weight
Mental Health Research Accelerator Act of 2025
Veterans Health Administration Novel Therapeutics Preparedness Act
Freedom to Heal Act of 2025
Freedom to Heal Act of 2025
Executive orders & memoranda affecting the same sectors or companies
This proclamation reaffirms U.S. leadership in space exploration, declaring outer space open to development and permanent settlement by American citizens. It sets goals for a return to the Moon by 2028 and a future Mars mission, while emphasizing support for the commercial space industry. The action does not invoke specific legal authorities or direct new funding but signals continued policy focus on space.
The President invokes Section 232 of the Trade Expansion Act to declare that imports of robotics, industrial machinery, and their components threaten national security, and directs the Secretary of Commerce and USTR to negotiate agreements with trading partners to adjust these imports, potentially leading to tariffs or quotas within 180 days.
This proclamation initiates negotiations to adjust imports of wind turbines and their components under Section 232, citing national security concerns including cybersecurity vulnerabilities, radar interference, and grid reliability. It does not immediately impose tariffs but sets the stage for potential trade restrictions, and notes that certain wind turbine components made of aluminum, steel, or copper are already subject to existing tariffs.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →